CMS is proposing temporary expansions of Medicare and Medicaid coverage of GLP-1s for obesity through demonstration programs CMS initially proposed a two-step approach to expanding coverage of GLP-1s for obesity in Medicare a temporary payment demonstration for 2026, known as the Medicare GLP-1 Bridge, and a new Center for Medicare and Medicaid Innovation (CMMI) model, known as the BALANCE Model, that was originally scheduled to begin in January 2027 and end in December 2031
It plays well with other molecules
Early and laterstage persistence with anti-obesity medications: A retrospective cohort study
Where does Prime Health operate
Inflammatory Microenvironment Research Both peptides are theorized to support the inflammatory milieu: BPC157 is believed to modulate cytokine signaling to support controlled inflammation and repair, while TB500 seems to reduce chronic inflammatory signaling and support tissue pliability
Neuromodulation There is substantial evidence demonstrating that liver neuroregulation influences hepatic metabolism, immunity, and regeneration processes